Seroprevalence of Human Cytomegalovirus IgG Antibodies and Risk Assessment of the Virus Infection among Pregnant Women in Tripoli, Libya
DOI:
https://doi.org/10.54361/LJMR.19.1.22Keywords:
Human cytomegalovirus, Seroprevalence, IgG, Pregnant women, Tripoli, LibyaAbstract
Background: HCMV infection is the most prevalent congenital viral infection around the world and the leading cause of sensorineural hearing loss in infants and young children. In Libya, only a few studies investigated the prevalence of HCMV infection among pregnant women. Due to these reasons, the purpose of this study is to identify the seroprevalence of anti-HCMV IgG in pregnant women who attended the reference medical laboratory—Tripoli. Additionally, to determine risk factors linked to HCMV IgG positivity in these pregnant women.Material and methods: A total of 97 serum samples were collected from pregnant women. The socioeconomic characteristics and risk factors for HCMV infection of every pregnant woman were collected via a questionnaire. Using the VIDAS CMV IgG (CMVG) assay, the sera of the pregnant women were tested for anti-HCMV IgG. The Statistical Package for Social Sciences (SPSS) version 26.0 statistical program was used to analyze the results.Results: Out of 97 pregnant women who participated in the study, 93 tested positive for an anti-HCMV IgG, yielding a seroprevalence of 95.8%. The seroprevalence of anti-HCMV IgG has no significant association with the type of ABO system, presence of antigen D, age group, place of residence, educational level, occupation, monthly income, gestational age, parity, abortion, stillbirths, and blood transfusion.Conclusion: The seroprevalence of anti-HCMV IgG among pregnant women in Tripoli, Libya, is high (95.8%), consistent with previous studies from underdeveloped nations. There was no significant association between HCMV IgG positivity and any risk factors associated with it An awareness program regarding HCMV infection, its potential risks, and transmission route is recommended.
Downloads
References
1. Ho M. (2008). The history of cytomegalovirus and its diseases. Medical microbiology and immunology, 197(2), 65–73.
2. Charles, O. J., Venturini, C., Gantt, S., Atkinson, C., Griffiths, P., Goldstein, R. A., & Breuer, J. (2023). Genomic and geographical structure of human cytomegalovirus. Proceedings of the National Academy of Sciences of the United States of America, 120(30), e2221797120.
3. Tomtishen J. P., 3rd (2012). Human cytomegalovirus tegument proteins (pp65, pp71, pp150, pp28). Virology journal, 9, 22.
4. He, L., Hertel, L., James, C. D., Morgan, I. M., Klingelhutz, A. J., Fu, T. M., Kauvar, L. M., & McVoy, M. A. (2024). Inhibition of human cytomegalovirus entry into mucosal epithelial cells. Antiviral research, 230, 105971.
5. Taxonomy. (2024). International Committee on Taxonomy of Viruses (ICTV). Available at: https://talk.ictvonline.org/taxonomy/ (Accessed: 30 September 2024).
6. Griffiths, P., & Reeves, M. (2021). Pathogenesis of human cytomegalovirus in the immunocompromised host. Nature reviews. Microbiology, 19(12), 759–773.
7. Nolan, N., Halai, U. A., Regunath, H., Smith, L., Rojas-Moreno, C., & Salzer, W. (2017). Primary cytomegalovirus infection in immunocompetent adults in the United States - A case series. IDCases, 10, 123–126.
8. Zuhair, M., Smit, G. S. A., Wallis, G., Jabbar, F., Smith, C., Devleesschauwer, B., & Griffiths, P. (2019). Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Reviews in medical virology, 29(3), e2034.
9. Ljungman, P., Boeckh, M., Hirsch, H. H., Josephson, F., Lundgren, J., Nichols, G., Pikis, A., Razonable, R. R., Miller, V., Griffiths, P. D., & Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum (2017). Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 64(1), 87–91.
10. Dioverti, M. V., & Razonable, R. R. (2016). Cytomegalovirus. Microbiology spectrum, 4(4), 10.1128/microbiolspec. DMIH2-0022-2015.
11. Weisblum, Y., Panet, A., Haimov-Kochman, R., & Wolf, D. G. (2014). Models of vertical cytomegalovirus (CMV) transmission and pathogenesis. Seminars in immunopathology, 36(6), 615–625.
12. Ssentongo, P., Hehnly, C., Birungi, P., Roach, M. A., Spady, J., Fronterre, C., Wang, M., Murray-Kolb, L. E., Al-Shaar, L., Chinchilli, V. M., Broach, J. R., Ericson, J. E., & Schiff, S. J. (2021). Congenital Cytomegalovirus Infection Burden and Epidemiologic Risk Factors in Countries With Universal Screening: A Systematic Review and Meta-analysis. JAMA network open, 4(8), e2120736.
13. Fowler, K. B., Ross, S. A., Shimamura, M., Ahmed, A., Palmer, A. L., Michaels, M. G., Bernstein, D. I., Sánchez, P. J., Feja, K. N., Stewart, A., & Boppana, S. (2018). Racial and Ethnic Differences in the Prevalence of Congenital Cytomegalovirus Infection. The Journal of pediatrics, 200, 196–201.e1.
14. Fowler K. B. (2013). Congenital cytomegalovirus infection: audiologic outcome. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 57 Suppl 4(Suppl 4), S182–S184.
15. Cantey, J. B., & Sanchez, P. J. (2011). Overview of congenital infections: the prominence of cytomegalovirus. Infectious disorders drug targets, 11(5), 426–431.
16. Kabani, N., & Ross, S. A. (2020). Congenital Cytomegalovirus Infection. The Journal of infectious diseases, 221(Suppl 1), S9–S14.
17. Manicklal, S., Emery, V. C., Lazzarotto, T., Boppana, S. B., & Gupta, R. K. (2013). The "silent" global burden of congenital cytomegalovirus. Clinical microbiology reviews, 26(1), 86–102.
18. Al-Ghani, S. A., Aljad, S. M., Abukhres, O. M., Mukhtar, I. A., Hawad, A. F., Al-Rasheed, H., & Shahlol, A. M. (2016). The Prevalence of Cytomegalovirus Infection in a Group of Pregnant Women in Brack Al-Shati, libya. INTERNATIONAL JOURNAL OF APPLIED MEDICAL AND BIOLOGICAL RESAERCH, 1 (1), 7-11.
19. Moglad, E. H., Hassan, A. O., Atta Elmanan, M. S., Saeed, S. M., Abdalla, W. M., Mohammedsalih, K. A., Ali, H. T., Abd Elaziz, M. S., & Ahmed, H. H. (2023). Seroepidemiological Survey of Cytomegalovirus Infection among Pregnant Women in Sudan. Polish journal of microbiology, 72(3), 269–275.
20. Alghalibi SMS, Abdullah QYM, Al-Arnoot S, Al-Thobhani A (2016) Seroprevalence of Cytomegalovirus among Pregnant Women in Hodeidah city, Yemen. J Hum Virol Retrovirol, 3(5): 00106.
21. Akinbami, A. A., Rabiu, K. A., Adewunmi, A. A., Wright, K. O., Dosunmu, A. O., Adeyemo, T. A., Osunkalu, V. O. (2011). Seroprevalence of cytomegalovirus antibodies amongst normal pregnant women in Nigeria. International Journal of Women’s Health, 3, 423–428.
22. Waseem, H., Ali, J., Jamil, S.U., Ali, A., & Jameel, S. (2017). Seroprevalence of Cytomegalovirus among pregnant women in Islamabad, Pakistan. Journal of entomology and zoology studies, 5, 1788-1791.
23. Bozarida, W., Jadullah, D. (2023). Prevalence of Human Cytomegalovirus (CMV) among Pregnant Libyan Women. Qurina Scientific Journal, 2(2), 32-46.
24. de la Calle, M., Rodríguez-Molino, P., Romero Gómez, M. P., & Baquero-Artigao, F. (2023). Cytomegalovirus seroprevalence in pregnant women in Madrid: First step for a systematic screening. Enfermedades infecciosas y microbiologia clinica (English ed.), 41(1), 55–56.
25. Enders, G., Daiminger, A., Lindemann, L., Knotek, F., Bäder, U., Exler, S., & Enders, M. (2012). Cytomegalovirus (CMV) seroprevalence in pregnant women, bone marrow donors and adolescents in Germany, 1996-2010. Medical microbiology and immunology, 201(3), 303–309.
26. Wujcicka, W., Gaj, Z., Wilczyński, J., Sobala, W., Spiewak, E., & Nowakowska, D. (2014). Impact of socioeconomic risk factors on the seroprevalence of cytomegalovirus infections in a cohort of pregnant Polish women between 2010 and 2011. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 33(11), 1951–1958.
27. Knowles, S. J., Grundy, K., Cahill, I., Cafferkey, M. T., & Geary, M. (2005). Low cytomegalovirus sero-prevalence in Irish pregnant women. Irish medical journal, 98(7), 210–212.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ali M. Albasheeri, Khadija Amara, Noura Almagrabi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
